Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 26, 2022; 10(30): 10840-10851
Published online Oct 26, 2022. doi: 10.12998/wjcc.v10.i30.10840
Published online Oct 26, 2022. doi: 10.12998/wjcc.v10.i30.10840
Role of visfatin in obesity-induced insulin resistance
Mona Mohamed Ibrahim Abdalla, Physiology Department, Human Biology Division, School of Medicine, International Medical University, Kuala Lumpur 57000, Bukit Jalil, Malaysia
Author contributions: Abdalla MMI collected the data and wrote the paper.
Conflict-of-interest statement: The author declares no conflict of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mona Mohamed Ibrahim Abdalla, MSc, PhD, Senior Lecturer, Physiology Department, Human Biology Division, School of Medicine, International Medical University, No. 126, 19 Jln Jalil Perkasa, Kuala Lumpur 57000, Bukit Jalil, Malaysia. monamohamed@imu.edu.my
Received: April 30, 2022
Peer-review started: April 30, 2022
First decision: May 29, 2022
Revised: June 13, 2022
Accepted: September 23, 2022
Article in press: September 23, 2022
Published online: October 26, 2022
Peer-review started: April 30, 2022
First decision: May 29, 2022
Revised: June 13, 2022
Accepted: September 23, 2022
Article in press: September 23, 2022
Published online: October 26, 2022
Core Tip
Core Tip: Visfatin is an adipocytokine that is produced by visceral fat and other sources. It has been shown to influence glucose and lipid metabolism, as well as enhance the chronic inflammatory state linked to obesity. The findings on the relationship between visfatin and IR in obese patients are controversial. This review aims to better understand how visfatin contributes to the emergence of IR and to assess the possibility of utilizing visfatin levels as a biomarker for the early detection of IR and IR-related diseases, including cardiovascular and renal diseases.